Fulltext

Production and characterization of monoclonal antibodies against pregnancy-associated plasma protein A

Bersinger, N.A. ; Meisser, A. ; Bessou, T. ; Seguin, P. ; Birkhäuser, M.H. ; Bischof, P.

In: Molecular Human Reproduction, 1999, vol. 5, no. 7, p. 675-681

Ajouter à la liste personnelle
    Titre
    • Production and characterization of monoclonal antibodies against pregnancy-associated plasma protein A
    Auteur
    • Bersinger, N.A.. Department of Obstetrics and Gynaecology, University of Berne, Schanzeneckstrasse 1, Berne CH-3012
    • Meisser, A.. Department of Obstetrics and Gynaecology, University of Geneva, Switzerland
    • Bessou, T.. CIS-Bio international, In Vitro Technologies Division, Bagnols-sur-Cèze, France
    • Seguin, P.. CIS-Bio international, In Vitro Technologies Division, Bagnols-sur-Cèze, France
    • Birkhäuser, M.H.. Department of Obstetrics and Gynaecology, University of Berne, Schanzeneckstrasse 1, Berne CH-3012
    • Bischof, P.. Department of Obstetrics and Gynaecology, University of Geneva, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Molecular Human Reproduction, 1999, vol. 5, no. 7, p. 675-681. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:299477
    Summary
    Pregnancy-associated plasma protein A (PAPP-A) was found to be a good first trimester maternal serum marker, together with free β-human chorionic gonadotrophin (HCG) subunits, for the biochemical screening of fetal trisomy 21 (Down's syndrome). We have raised monoclonal antibodies (mAbs) against PAPP-A purified from human pregnancy serum. The different antibodies were characterized biochemically by Western blot analysis and in terms of specificity (reaction with non-pregnant and male serum). Their performance in Down's syndrome screening was assessed in comparison with an existing enzyme-linked immunosorbent assay method after labelling of the different mAbs with biotin or horseradish peroxidase. A pair of mAbs was eventually chosen for a double-antibody sandwich protocol. The selected combination was found to have a significantly increased specificity (P = 0.0116) over the method using (purified) polyclonal antibodies, together with slightly increased sensitivity. In our limited number of Down's syndrome pregnancy samples (n = 17) and controls (n = 18), the medians as well as the multiples of the median values (for the affected cases) were comparable between the two methods described